

South Africa

Population 2014

54 million

Estimates of TB burden * 2014	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	24 (22–26)	44 (41–48)
Mortality (HIV+TB only)	72 (58–89)	134 (107–164)
Prevalence (includes HIV+TB)	380 (210–590)	696 (390–1 088)
Incidence (includes HIV+TB)	450 (400–510)	834 (737–936)
Incidence (HIV+TB only)	270 (240–310)	509 (439–584)

Case detection, all forms (%)	68 (61–77)
-------------------------------	------------

Estimates of MDR-TB burden * 2014	New	Retreatment
% of TB cases with MDR-TB	1.8 (1.4–2.3)	6.7 (5.4–8.2)
MDR-TB cases among notified pulmonary TB cases	4 700 (3 700–5 900)	1 500 (1 200–1 800)

TB case notifications 2014	New **	Relapse
Pulmonary, bacteriologically confirmed	155 473	7 430
Pulmonary, clinically diagnosed	106 482	2 693
Extrapulmonary	33 522	566

Total new and relapse	306 166
Previously treated, excluding relapses	12 027
Total cases notified	318 193

Among 306 166 new and relapse cases:
31 977 (10%) cases aged under 15 years; male:female ratio: 1.3

Reported cases of RR-/MDR-TB 2014	New	Retreatment	Total **
Cases tested for RR-/MDR-TB			218 231
Laboratory-confirmed RR-/MDR-TB cases			18 734
Patients started on MDR-TB treatment ***			11 538

TB/HIV 2014	Number	(%)
TB patients with known HIV status	295 136	(93)
HIV-positive TB patients	179 756	(61)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	155 017	(86)
HIV-positive TB patients on antiretroviral therapy (ART)	141 755	(79)
HIV-positive people screened for TB	1 148 477	
HIV-positive people provided with IPT	551 787	

Treatment success rate and cohort size	(%)	Cohort
New and relapse cases registered in 2013	(78)	321 087
Previously treated cases, excluding relapse, registered in 2013	(69)	18 292
HIV-positive TB cases, all types, registered in 2013	(76)	191 189
RR-/MDR-TB cases started on second-line treatment in 2012	(49)	8 084
XDR-TB cases started on second-line treatment in 2012	(20)	607

Laboratories 2014	
Smear (per 100 000 population)	0.4
Culture (per 5 million population)	1.1
Drug susceptibility testing (per 5 million population)	1.1
Sites performing Xpert MTB/RIF	207
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2015	
National TB programme budget (US\$ millions)	248
% Funded domestically	84%
% Funded internationally	8%
% Unfunded	8%


* Ranges represent uncertainty intervals

** Includes cases with unknown previous TB treatment history

*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population)




— Prevalence

(Rate per 100 000 population per year)




— Notified (new and relapse) — Incidence
— Incidence (HIV+TB only)

(Number of patients)




— HIV-positive TB patients
— on CPT — on ART

Treatment success rate (%)



— New — Retreatment
— New and relapse — Retreatment, excluding relapse
— HIV-positive — RR-/MDR-TB — XDR-TB

Total budget (US\$ millions)



— Funded domestically — Funded internationally
— Unfunded